Prostatic Neoplasms
Conditions
Brief summary
A study to investigate the activity of BI 2536 in Prostate Cancer
Interventions
DRUGBI 2536
Sponsors
Boehringer Ingelheim
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male patient age \>18 years. * Signed informed consent. * Able to comply with protocol requirements. * Patients with histologically, cytologically or biochemically documented metastatic adenocarcinoma of the prostate, clinically refractory or resistant to hormone therapy, as documented by progression following at least one hormonal therapy, which must include orchidectomy or gonadotropin releasing hormone agonist (GnRHa). * Patients with Progressive Disease (PD). PD is defined as a minimum of three consecutive serum PSA measurements obtained at least 7 days apart within the previous 3 months of start of trial, which document progressively increasing PSA values. Patients with progression of measurable disease (RECIST) or progression of bone disease must also fit the criterion for PSA progression. * Patients must have documented progression (as defined above) following anti-androgen withdrawal of 4 weeks duration for flutamide and 6 weeks for bicalutamide or nilutamide. For a patient who has withdrawn from anti-androgen therapy less than 6 months prior to inclusion in the trial, one of the following criteria is also required: * Following completion of the anti-androgen withdrawal period one PSA measurement should be higher than the last pre-withdrawal PSA. Or * Following the completion of the anti-androgen withdrawal period if the PSA value has decreased, a patient can still qualify if 2 increases in PSA are documented after the post- withdrawal nadir. * PSA \> 10 ng/ml. * A predicted life expectancy of at least 12 weeks. * A maximum of one prior treatment with either chemotherapy or other non-hormonal treatment modality. * ECOG performance status 0-1. * Stable analgesia requirements. * INR Prothrombin time (PT) and partial thromboplastin time (PTT) \<1.5 upper limit of normal. * Adequate bone marrow function defined as absolute neutrophil count (ANC) \> 1.5 x 109l, Platelet count \> 100 x 109/l. * Haemoglobin \> 9.0 mg/dl. * Serum Albumin \> 2.0 g/l. * Castrate testosterone level \[\< 20 ng/dl or \<0.69nM (nM/L x 28.8 = ng/dl)\] must be maintained during the duration of the trial by orchidectomy or medical castration. * Patients on oral or intravenous bisphosphonates are allowed to enter the trial as long as they have been on bisphosphonates for a minimum of 3 months.
Exclusion criteria
* Prior treatment with more than one cytotoxic chemotherapy regimen. * Known or suspected hypersensitivity to the trial drug or their excipients. * Persistence of toxicities of prior anti-cancer therapies which are deemed to be clinically relevant. * Aspartate amino transferase (ast) or alanine amino transferase (alt) greater than 2.5 times the upper limit of normal, or aspartate amino transferase (ast) or alanine amino transferase (alt) greater than 5 times the upper limit of normal in case of known liver metastases. * Bilirubin greater than 1.5 mg/dl (\> 26 micromol/l, Si unit equivalent). Serum creatinine greater than 2.0 g/l. * Concomitant intercurrent illnesses including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness or social situation that would limit compliance with trial requirement or which are considered relevant for the evaluation of the efficacy or safety of the trial drug. * Systemic corticosteroids taken within the past 28 days before screening (inhaled corticosteroids prescribed for bronchospasm are allowed). Patients on long-term stable-dose steroids for concurrent illness are not excluded. * Treatment with any investigational drug within 28 days of trial onset. * History of other malignancies which could affect compliance with the protocol or interpretation of results within 5-years. Patients with adequately treated basal or squamous cell skin cancer are generally eligible. * Patient with history or clinical evidence of CNS disease or brain metastases. * Patients with symptoms of impending or established spinal cord compression. * Radiotherapy within the past four weeks prior to treatment with the trial drug. * Prior radioisotope therapy (except radium-223 which is permissible). * Immunotherapy within the past four weeks prior to treatment with the trial drug. * Patients unable to comply with the protocol. * Active alcohol or drug abuse. * Patients who do not use adequate contraception.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PSA response rate at 12 weeks according to Prostate Specific Antigen Working Group (PSAWG) criteria. | 12 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Time to PSA progression assessed at 24 weeks | 24 weeks |
| Overall objective response using RECIST criteria (complete response [CR] or partial response [PR]) in patients with measurable disease | at least 12 weeks |
| Time to death | at least 12 weeks |
| Time to overall progression | at least 12 weeks |
| Progression free survival | at least 12 weeks |
| PSA response duration | at least 12 weeks |
| Duration of overall response (RECIST) | at least 12 weeks |
| BI 2536 plasma concentrations | 1 week |
| Incidence and intensity of AEs, with grading according to the US National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE, version 3.0) | 24 weeks |
| Number of patients with changes in laboratory safety parameters | 24 weeks |
| Overall survival | at least 12 weeks |
Countries
United Kingdom
Outcome results
None listed